Cipla Lands First AB-Rated Generic for Ventolin HFA

Cipla has secured USFDA approval for the first AB-rated generic therapeutic equivalent of Ventolin HFA, a development that repositions the Mumbai-based manufacturer at the front of the queue in one of the most technically demanding segments of the ANDA pipeline: pressurised metered-dose inhalers.

The AB rating is the operative detail here. Under FDA's therapeutic equivalence framework, an AB-rated product is substitutable at the pharmacy level without prescriber intervention, giving Cipla immediate commercial access to a market previously protected by the complexity of inhaler device development and the regulatory bar set by the 21 CFR Part 211 and product-specific guidance for orally inhaled drug products. For plant heads and QA directors managing respiratory manufacturing lines, the approval signals that Cipla's aerosol development and sterility assurance protocols have met the agency's full evidentiary standard for equivalence.

For the broader industry, the approval carries strategic weight beyond a single product. Complex inhaler generics have historically been a bottleneck for Indian manufacturers, requiring device-drug combination data, formulation equivalence, and in vitro and in vivo testing that extends development timelines well past conventional oral solid dose programmes. A first-to-file or first-approved position on a product of this profile directly informs competitor ANDA strategy and signals where respiratory manufacturing investment is likely to concentrate over the next planning cycle.

Source: Media4Growth / Indian Pharma Post, published 26 April 2026. Pharma Now has reported facts as stated in the source article. No additional data was independently verified at time of publication.